InsiderTrades

Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-16 · accession 0000950170-25-023630 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-02-19 2025-02-19 BBIO STEPHENSON BRIAN C CFO, Sec, Treas S - Sale+OE $36.16 -4,148 102.5K -4% -$150.0K
DT 2025-02-19 2025-02-16 BBIO STEPHENSON BRIAN C CFO, Sec, Treas F - Tax $34.90 -13.1K 106.6K -11% -$457.3K
DT 2025-02-19 2025-02-16 BBIO STEPHENSON BRIAN C CFO, Sec, Treas M - OptEx — +25.8K 119.7K +27% —
DMT 2025-02-19 2025-02-16 BBIO STEPHENSON BRIAN C CFO, Sec, Treas M - OptEx $0.00 -25.8K 2,840 -90% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-19 S D 4,148 $36.16 102,464 D — — (F5) Represents the weighted average sale price of the shares sold from $35.57 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2 Common Common Stock 2025-02-16 F D 13,102 $34.90 106,612 D — — (F3) Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,798 shares of Common Stock underlying the Reporting Person's RSUs.
3 Common Common Stock 2025-02-16 M A 25,798 — 119,714 D — — (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F2) Includes 158 shares of the Issuer's Common Stock acquired by the Reporting Person on February 14, 2025 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
4 Derivative Restricted Stock Units 2025-02-16 M D 779 $0.00 0 D — · — to — 779 Common Stock (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F6) The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date.
5 Derivative Restricted Stock Units 2025-02-16 M D 6,705 $0.00 80,459 D — · — to — 6,705 Common Stock (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F9) The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
6 Derivative Restricted Stock Units 2025-02-16 M D 17,368 $0.00 138,947 D — · — to — 17,368 Common Stock (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F8) The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
7 Derivative Restricted Stock Units 2025-02-16 M D 946 $0.00 2,840 D — · — to — 946 Common Stock (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F7) The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.